Press Releases

Published from:


Showing 31 - 45 of 4019 between Jan 2004 and Mar 2018

Adults in behavioral interventions can meaningfully engage with media production activities, like modifying advertising slogans and creating truthful nutrition labels, which have been shown to help demystify media messages, according to a new study published in the Journal of Nutrition Education and Behavior

International experts debate the merits of available standards for assessing fetal growth and birthweight and other measures for achieving the best birth outcomes in a supplement to the American Journal of Obstetrics & Gynecology

Via Oncology, recently acquired by Elsevier, including expert-defined clinical algorithms and specific recommendations for all significant aspects of cancer care

Designed after consulting with medical students and faculty across the globe, ClinicalKey Medical Education engages learners and helps to turn medical information into knowledge

A new study in Biological Psychiatry investigates the molecular basis for male predisposition to autism

A new study in Biological Psychiatry: Cognitive Neuroscience and Neuroimaging looks at the modulation of emotion in the brain

First large-scale investigation of AF in Taiwan shows increasing risks, according to a new study in the journal CHEST®

Outcomes seek to explore how machine learning and data analytics can guide researchers

A randomized, double-blind, placebo-controlled trial published in Biological Psychiatry shows that sodium benzoate improves symptoms in clozapine-resistant schizophrenia

Elsevier’s collaboration with the National University of Science and Technology MISIS will be expanded to support its engineering research and innovation projects

Patients in Nova Scotia who are farther away from Halifax have higher mortality, according to a new study in the Canadian Journal of Cardiology

Start-ups working on a range of technologies and discoveries – from AI to immunotherapy – receive complimentary access to Elsevier’s information solutions to accelerate innovation

For second year in a row, global evidence-based solution recognized in ‘Clinical Decision Support – Care Plans/Order Sets’ category

Intravenous bevacizumab should be considered as a first-line therapy for the treatment of refractory bleeding in patients with severe hereditary hemorrhagic telangiectasia, reports Mayo Clinic Proceedings